FBI LOGO TM.png
Graft Versus Host Disease Treatment Market Report 2021-2028 | Size, Share, Growth Factors, Restraining Factors, Revenue, Competitive Landscape, Forecast Analysis
October 14, 2021 06:23 ET | Fortune Business Insights
Pune, India, Oct. 14, 2021 (GLOBE NEWSWIRE) -- The global “graft versus host disease treatment market” size is slated to experience a rugged expansion period on account of rising number of allogenic...
MSB_logo_notag (001).jpg
Mesoblast’s Japan Licensee Receives Pricing for TEMCELL® HS Inj. for Treatment of Acute Graft Versus Host Disease
November 27, 2015 06:00 ET | Mesoblast Limited
MELBOURNE, Australia and NEW YORK, Nov. 27, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today announced that its licensee in Japan, JCR Pharmaceuticals Co. Ltd., has received...
Mesoblast Chairman's Address to 2015 Annual General Meeting
October 22, 2015 02:00 ET | Mesoblast
NEW YORK, Oct. 22, 2015 (GLOBE NEWSWIRE) -- Thank you for attending the Mesoblast 2015 Annual General Meeting. This has been another exciting and productive year in the history of our...
Full Product Approval In Japan Received By Mesoblast Licensee
September 18, 2015 01:23 ET | Mesoblast
NEW YORK CITY and MELBOURNE, Australia, Sept. 18, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today announced that its licensee JCR Pharmaceuticals Co. Ltd has received full...
Mesoblast Partner JCR Pharmaceuticals Receives Recommendation For Approval Of Mesenchymal Stem Cell Product In Japan
September 03, 2015 20:44 ET | Mesoblast
NEW YORK and MELBOURNE, Australia, Sept. 3, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today announced that the allogeneic mesenchymal stem cell-based regenerative medicine...
Mesoblast Reports 2015 Financial Year Results And Provides Update On Phase 3 Chronic Heart Failure Program
August 16, 2015 20:28 ET | Mesoblast
NEW YORK and MELBOURNE, Australia, Aug. 16, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today reported its 2015 full financial year results, and provided an update on important...
Mesoblast Partner JCR Pharmaceuticals Files for Marketing Approval of the First Allogeneic Stem Cell Product in Japan
September 30, 2014 20:17 ET | Mesoblast
NEW YORK and MELBOURNE, Australia, Sept. 30, 2014 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today reported that its Japanese partner, JCR...
Mesoblast Unveils Path to Bring Its Key Products to Market
August 25, 2014 20:27 ET | Mesoblast
NEW YORK and MELBOURNE, Australia, Aug. 25, 2014 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today reported 2014 financial results and unveiled its...
Mesoblast Reports Strong Half-Year Financial Results
February 25, 2014 17:00 ET | Mesoblast
NEW YORK and MELBOURNE, Australia, Feb. 25, 2014 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today provided its 2014 half-year financial results and...
IMPROVED SURVIVAL IN CHILDREN WITH LIFE THREATENING GRAFT VERSUS HOST DISEASE REPORTED AFTER TREATMENT WITH MESOBLAST'S CELL THERAPY
November 13, 2013 19:22 ET | Mesoblast
NEW YORK and MELBOURNE, Australia, Nov. 13, 2013 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB) (USOTC:MBLTY) today announced that a peer-reviewed article in the...